These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19639037)

  • 1. A model and risk score for predicting nevirapine-associated rash among HIV-infected patients: in settings of low CD4 cell counts and resource limitation.
    Kiertiburanakul S; Sungkanuparph S; Malathum K; Watcharananan S; Sathapatayavongs B; Charoenyingwattana A; Mahasirimongkol S; Chantratita W
    Open AIDS J; 2009 Jul; 3():24-30. PubMed ID: 19639037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings.
    Kiertiburanakul S; Sungkanuparph S; Charoenyingwattana A; Mahasirimongkol S; Sura T; Chantratita W
    Curr HIV Res; 2008 Jan; 6(1):65-9. PubMed ID: 18288977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
    Kiertiburanakul S; Malathum K; Watcharananan S; Sathapatayavongs B; Sungkanuparph S
    Int J STD AIDS; 2009 Mar; 20(3):176-9. PubMed ID: 19255265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
    Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
    Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash.
    Chantarangsu S; Mushiroda T; Mahasirimongkol S; Kiertiburanakul S; Sungkanuparph S; Manosuthi W; Tantisiriwat W; Charoenyingwattana A; Sura T; Takahashi A; Kubo M; Kamatani N; Chantratita W; Nakamura Y
    Clin Infect Dis; 2011 Aug; 53(4):341-8. PubMed ID: 21810746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.
    Chantarangsu S; Mushiroda T; Mahasirimongkol S; Kiertiburanakul S; Sungkanuparph S; Manosuthi W; Tantisiriwat W; Charoenyingwattana A; Sura T; Chantratita W; Nakamura Y
    Pharmacogenet Genomics; 2009 Feb; 19(2):139-46. PubMed ID: 19104471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
    Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
    HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.
    Coffie PA; Tonwe-Gold B; Tanon AK; Amani-Bosse C; Bédikou G; Abrams EJ; Dabis F; Ekouevi DK
    BMC Infect Dis; 2010 Jun; 10():188. PubMed ID: 20576111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.
    Manosuthi W; Thongyen S; Chumpathat N; Muangchana K; Sungkanuparph S
    HIV Med; 2006 Sep; 7(6):378-82. PubMed ID: 16903982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
    van Leth F; Andrews S; Grinsztejn B; Wilkins E; Lazanas MK; Lange JM; Montaner J;
    AIDS; 2005 Mar; 19(5):463-71. PubMed ID: 15764851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.
    Ananworanich J; Moor Z; Siangphoe U; Chan J; Cardiello P; Duncombe C; Phanuphak P; Ruxrungtham K; Lange J; Cooper DA
    AIDS; 2005 Jan; 19(2):185-92. PubMed ID: 15668544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity.
    Patterson P; Socías E; Pryluka D; Lapadula P; Pérez H; Cahn P
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19794. PubMed ID: 25397538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cutaneous drug-reactions to nevirapine: study of risk factors in 101 HIV-infected patients].
    Pitche P; Drobacheff-Thiebaut C; Gavignet B; Mercier M; Laurent R
    Ann Dermatol Venereol; 2005 Dec; 132(12 Pt 1):970-4. PubMed ID: 16446639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.
    Montaner JS; Cahn P; Zala C; Casssetti LI; Losso M; Hall DB; Wruck J; McDonough M; Gigliotti M; Robinson PA;
    J Acquir Immune Defic Syndr; 2003 May; 33(1):41-6. PubMed ID: 12792354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
    HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?
    Notter J; Bregenzer A; Vernazza P; Kahlert CR
    Swiss Med Wkly; 2019 Apr; 149():w20053. PubMed ID: 31017649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
    HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.
    Bera E; Mia R
    S Afr Med J; 2012 Oct; 102(11 Pt 1):855-9. PubMed ID: 23116743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.
    Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Inthong Y; Prasithsirikul W; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chumpathat N; Termvises P; Chaovavanich A
    Int J STD AIDS; 2007 Nov; 18(11):782-6. PubMed ID: 18005514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.